ABSTRACT: Background: Stereoelectroencephalography has been in regular use at the Montreal Neurological Institute since 1972. The technique has been in constant evolution to incorporate advances in materials, imaging, and robotics technology. MRI-compatible electrodes were introduced in 2007 and robotics in 2011. Here we report on the technique, safety, and advantages of our current method of stereoelectroencephalography implantation. Methods: We retrospectively reviewed all patients who underwent stereoelectroencephalography by the senior author. Technical, clinical, and radiological complications, and postimplantation outcomes were analyzed. Only patients implanted with MRI-compatible electrodes were included to review MRI abnormalities with electrodes in situ. Results: A total of 53 patients were implanted with 550 electrodes (average = 10.4 per patient), for an average duration of 14.6 days. There was no mortality, infection, or new neurologic deficit. Two patients had a superficial screw plunge without clinical consequence. Four patients demonstrated asymptomatic MRI abnormalities (7.54% per patient, or 0.72% per electrode). MRI with electrodes in situ was used for neuronavigation in all 29 who underwent resection and yielded a histopathological diagnosis of focal cortical dysplasia in 15 MRI-negative patients. Conclusions: The technique of stereoelectroencephalography described here was associated with no clinical morbidity although not without technical complications or radiologic (MRI) abnormalities. We should therefore remain vigilant in refining the technique and minimizing the number of electrodes required to answer a well-developed hypothesis regarding the epileptogenic zone. The use of MRI-compatible electrodes allowed neuronavigation using the images with the electrodes in situ, which was useful to tailor the eventual definitive resection and in localizing MRI-negative lesions.
INTRODUCTION
Image-guided placement of intracranial surface and depth electrodes for the characterization of epileptic foci was first promoted 52 years ago 1 and is currently a crucial step in the presurgical evaluation of many patients with pharmacoresistant epilepsy. Stereoelectroencephalography (SEEG) was developed in Paris using a frame-based method that made use of intraoperative angiography to avoid vascular complications. 2 The aim of SEEG is to determine the epileptogenic zone-that is, the region of ictal onset and immediate spread-in three dimensions. It was first implemented at the Montreal Neurological Institute in 1972 3 and has been associated with a very low rate of morbidity. 4, 5 The procedure has been in constant evolution to take advantage of advances in materials and innovation in imaging and robotics technology. We began using magnetic resonance imaging (MRI)-compatible electrodes (DIXI Microtechniques, Besancon, France) in 2007 and a Robotic Surgical Assistant (ROSA, Medtech, Montpellier, France) in 2011. Previous studies have shown a greater degree of accuracy with the robot-assisted technique. 6, 7 SEEG electrodes from historical cases were not MRI-compatible, and thus a thorough review of MRI findings was not possible. In our study, for the first time, we showed MRI findings in a relatively large cohort of patients with pharmacoresistant epilepsy who had MRI with electrodes in situ following implantation of SEEG electrodes. We describe the current technique of SEEG implantation at our center and aim to assess its safety and advantages.
METHODS
We performed a retrospective chart review of all patients with MRI-compatible intracranial SEEG electrodes implanted by the senior author (JH). The research ethics board of the Montreal Neurological Institute and Hospital approved the review (no. NEU-14-101). All patients had preoperative enhanced MRI for image guidance during implantation of SEEG electrodes as well as postimplantation MRI with the electrodes in situ.
Initially, electrodes were inserted using a frameless technique with a double-chuck articulated arm 8 and the StealthStation neuronavigation system (Medtronic, Minneapolis, MN, United States) with image guidance by global acquisition gadolinium-enhanced MRI. Avascular trajectories were chosen from the scalp entry point to the intracranial target. Once the plane was obtained, a percutaneous craniostomy was performed with a 1.3-mm drill bit. A hollow anchoring screw measuring 2.5 cm in length was then secured in place with an adapted screwdriver (DIXI). The neuronavigation system was used to calculate the distance from the tip of the anchoring screw to the target. This distance was then translated to a measuring tool (DIXI), and a stylet (DIXI) was passed through the hollow screw to make a path for the electrode. Coagulation was sometimes required if the dura had not been breached by the anchoring screw. When the stylet was removed, the electrode was inserted to the proper depth and secured to the anchoring screw. The electrodes measure 0.8 mm in diameter.
Since 2011, we used ROSA for stereotaxy and the StealthStation neuronavigation system for verification and for depth measurement in all cases. Avascular trajectories are planned on the ROSA software with image guidance using global acquisition gadolinium-enhanced MRI coregistered onto global acquisition thin-cut computed tomography (CT) angiography (slice thickness = 1 mm). The stereotaxic craniostomy, anchoring screw, and electrode placement are identical to that described above.
The anchoring screws are made of titanium and the electrodes are made of platinum and iridium (DIXI Microtechniques, Besancon, France). Preimplantation CT angiography for stereotaxy planning was acquired using a Toshiba CT machine (Aquilion ONE, Toshiba, Tokyo, Japan). Both preimplantation MRI for stereotaxy planning and postimplantation MRI (T1-and T2-weighted images) with electrode in situ was acquired using a 1. Postimplantation MRI images with electrodes in situ were employed for evaluation of complications and to reconstruct global images for later use in neuronavigation protocols during resection of the epileptic focus. While there is some metallic artifact, the electrodes and electrode contacts are best visualized on T2-weighted images. T1-weighted images were employed as reference in our neuronavigation protocols, and the T2-weighted images were coregistered.
A total of 55 consecutive patients were identified from September of 2007 to June of 2017. Two patients were excluded from analysis: one because not all of the implanted electrodes were MRI-compatible and postimplantation MRI was not acquired, and the other because it was not performed for SEEG (but for thermoablation). This was done to provide a homogenous cohort of patients undergoing SEEG for pharmacoresistant epilepsy, all of whom had MRI with the electrodes in situ. The MRI images with electrodes in situ were used for image guidance at the time of definitive resection in all patients.
The factors studied included technique of implantation (manual vs. robotic-assisted), radiological morbidity, clinical morbidity, and mortality. We also calculated the MRI-positive rate of patients diagnosed with focal cortical dysplasia (FCD) on histopathology. The MRI findings were extracted from the neuroradiology report of our center based on 1.5-Tesla MRI.
RESULTS
The details pertaining to semiology, MR findings, FDG-PET, and neuropsychology findings of the patients are summarized in Table 1 . Both of the techniques described here allowed successful implantation in all cases. Between September of 2007 and March of 2011, 20 patients (11 males; mean age = 34.6 ± 9.8 years, range =18-53) were implanted using the manual technique with a total of 184 electrodes (Table 1 , patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Between July of 2011 and June of 2017, 33 patients (23 males; mean age = 30.1 ± 9.4 years, range = 14-53) were implanted using the robot-assisted technique with a total of 366 electrodes (Table 1 , patients 21-53). Therefore, among the 53 patients included in our analysis, 550 electrodes were implanted, for an average of 10.4 per patient. The duration of implantation ranged from 7 to 31 days, with an average of 14.6 days.
Placement of the anchoring screw requires gentle forward pressure with the screwdriver to secure it to the bone. On two occasions, both associated with the electrodes placed through the temporal bone for hippocampal targets, the screw penetrated the cortex. In these two cases, a 1-cm incision and enlargement of the craniostomy was required to retrieve the screw found at the level of the inner table. While this technical complication resulted in no clinical consequences, its description is mentioned here due to highlight the need for very gentle pressure upon placement. We had no complications associated with removal of the electrodes. In all cases, they were removed with the short-handled screwdriver or the spanner made by DIXI to avoid plunging. Overall, there was no mortality, no neurologic deficit, and no infection observed. One patient developed headache 3 months after explantation of SEEG electrodes due to a venous thrombosis that resulted in edema in the left parietal lobe. However, an association between implantation and the venous thrombosis is unclear. The patient was treated with anticoagulants for 6 months and is now symptom-free.
A typical T2-weighted axial image is shown in Figure 1A . When seen along its plane, the electrode and each electrode contact are well-visualized. Figure 1B shows a sagittal T1-weighted image demonstrating the degree of metallic artifact. The actual diameter of the electrode is 0.8 mm. 
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A careful review of each patient's MRI with the electrodes in situ revealed four unexpected findings (three in the manual group and one in the robot-assisted group, p = 0.287). Figure 2A demonstrates an area of contusion without hemorrhage that resulted from a penetration of the anchoring screw through bone that had been weakened by previous pin fixation with the manual technique. Figure 2B shows a hemorrhagic contusion that likely occurred from an unintended perforation of the dura and cortex at the time of craniostomy with the manual technique. Figure 2C shows a subdural hematoma that likely occurred from an unintended perforation of the dura and/or laceration of a cortical vessel at the time of craniostomy with the manual technique. Figures 3A  and 3B show venous congestion in the left posterior temporal area, most likely secondary to venous compression or coagulation with the robot-assisted technique. Figures 3C and 3D demonstrate its resolution at 3 months post-explantation.
Among the 49 patients in whom the SEEG findings were finalized, 31 (63%) underwent therapeutic intervention (29 resections and 2 thermocoagulations). The MRI images with electrodes in situ were used for neuronavigation in all 29 who underwent resection. Seventeen patients were diagnosed with FCD on histopathology, while only 2 were positive for FCD on multiple preoperative MRI.
DISCUSSION
The goal of the present study is to assess the safety and advantages of the current SEEG electrode implantation methodology in our center. Accuracy of frameless SEEG techniques has been extensively reported, 6, 9, 10 and this is not our aim here. Among the 53 patients who were implanted for an average duration of 2 weeks, with an average number of 10 electrodes, there was no mortality, no infection, and no new neurologic deficit. This rate of clinical complication is lower than that associated with other types of intracranial recording such as subdural strips or grids. 11, 12 Although the number of patients in this study is relatively small, the low rate of clinical complications with our technique is encouraging, as it is comparable to large series reported recently. 7, 13, 14 Careful review of postimplantation MRI with electrodes in situ revealed four patients with asymptomatic radiological findings on MRI: three in the manual group and one in the robot-assisted group. The overall rate of asymptomatic radiologic complication was 7.54% per patient, or 0.72% per electrode. The overall rate of radiologic complication is slightly higher than that reported in a recent study. 15 However, the modalities used for postimplantation evaluation of complication were different: CT in previous studies and MRI in this study. The difference in radiologic complication rate may be explained by the difference of sensitivity in detecting abnormalities between MRI and CT: MRI (in this study) is more sensitive than CT (in previous studies). Nevertheless, only one hemorrhagic complication was found in this series (1.9% per patient, or 0.18% per electrode) and this rate is the same or even lower than the hemorrhagic complication based on CT findings in previous studies. 4, 7, 9, 15 While the use of robotics in neurosurgery remains in its infancy, 16 the application to stereotactic procedures is advancing rapidly. [17] [18] [19] The present study revealed that robotic assistance is safe to apply to stereotactic procedures.
A novel advantage provided by this technique is the ability to use the MRI with electrodes in situ for image-guided neuronavigation at the time of definitive resection. Under the guidance of MRI with electrodes in situ, resection yielded successful histopathological diagnosis of FCD in 15 patients who were MRInegative for FCD (88.2% of all patients with FCD in this series). This suggests that neuronavigation using MRI images with electrodes in situ was useful to tailor definitive resection of the socalled "non-lesional" cases, which are often shown to be FCD on histopathology.
The safety of MR imaging of implanted depth electrodes has been a matter of debate. 20 Despite evidence of studies demonstrating its safety under certain conditions, [20] [21] [22] postimplantation MRI is still less popular to date because of safety concerns among some neuroradiologists and neurosurgeons. In agreement with previous studies, we did not find any complication after MR imaging in this series of patients. This further supports the safe use of MR imaging in localizing the implanted SEEG electrodes.
LIMITATIONS OF THE STUDY
While many centers are now moving towards 3-T MR imaging capabilities, the use of 1.5-T MR imaging in our presurgical workup is a limitation in terms of identification of focal cortical dysplasia, or any potential epileptogenic lesion. This may in part explain the patient cohort in whom our preimplantation MRI failed to identify focal cortical dysplasia.
Other limitations include the small number of patients and the retrospective nature of our study. Hence, the safety and complication rate figures reported here need to be taken with caution. The safety of our SEEG implantation methodology and the usefulness of MRI with SEEG in situ in clinical practice will be better demonstrated in a larger controlled prospective study.
CONCLUSIONS
We reported the technique, safety, and advantages of the current SEEG implantation methodology in our center. This is also the first reported series of MRI findings of patients with SEEG electrodes in situ. While the radiological changes were few and none were clinically significant, it nonetheless suggests that we should remain vigilant in refining the technique and restrict the number of electrodes to the minimum required to study a welldefined preoperative hypothesis regarding the seizure onset zone and propagation pathway. The use of MRI-compatible electrodes allows neuronavigation using the images with the electrodes in situ, which is useful to tailor the eventual definitive surgical resection.
